Have a feature idea you'd love to see implemented?
Let us know!
HALO Halozyme Therapeutics Inc
Price (delayed)
$46.96
Market cap
$5.97B
P/E Ratio
15.3
Dividend/share
N/A
EPS
$3.07
Enterprise value
$7.32B
Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in
Highlights
The company's equity has surged by 82% YoY and by 56% QoQ
HALO's EPS has surged by 61% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of HALO
Market
Valuations
Earnings
Shares outstanding
127.23M
Market cap
$5.97B
Enterprise value
$7.32B
Price to book (P/B)
13.14
Price to sales (P/S)
6.29
EV/EBIT
14.68
EV/EBITDA
12.62
EV/Sales
7.73
Revenue
$947.36M
Gross profit
$777.7M
Net income
$392.47M
EBIT
$498.87M
EBITDA
$580.46M
Free cash flow
$392.71M
Per share
Balance sheet
Liquidity
EPS
$3.07
EPS diluted
$3.02
Free cash flow per share
$3.1
Book value per share
$3.57
Revenue per share
$7.47
TBVPS
$10.1
Total assets
$2.12B
Total liabilities
$1.67B
Debt
$1.5B
Equity
$452.7M
Working capital
$1.02B
Debt to equity
3.32
Current ratio
10.36
Quick ratio
8.75
Net debt/EBITDA
2.33
Margins
Efficiency
Dividend
EBITDA margin
61.3%
Gross margin
82.1%
Net margin
41.4%
Operating margin
50.4%
Return on assets
20.5%
Return on equity
156.4%
Return on invested capital
21.9%
Return on capital employed
24.8%
Return on sales
52.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HALO stock price
How has the Halozyme Therapeutics stock price performed over time
Intraday
-0.76%
1 week
-2.17%
1 month
2.62%
1 year
29.08%
YTD
27.06%
QTD
-17.96%
Financial performance
How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$947.36M
Gross profit
$777.7M
Operating income
$477.01M
Net income
$392.47M
Gross margin
82.1%
Net margin
41.4%
HALO's net income has surged by 55% year-on-year and by 16% since the previous quarter
The company's operating income has surged by 53% YoY and by 19% QoQ
HALO's gross profit is up by 30% YoY and by 11% QoQ
The net margin has grown by 27% YoY and by 7% from the previous quarter
Growth
What is Halozyme Therapeutics's growth rate over time
Valuation
What is Halozyme Therapeutics stock price valuation
P/E
15.3
P/B
13.14
P/S
6.29
EV/EBIT
14.68
EV/EBITDA
12.62
EV/Sales
7.73
HALO's EPS has surged by 61% year-on-year and by 18% since the previous quarter
The stock's price to earnings (P/E) is 50% less than its 5-year quarterly average of 30.5 and 16% less than its last 4 quarters average of 18.2
The company's equity has surged by 82% YoY and by 56% QoQ
HALO's price to book (P/B) is 66% lower than its 5-year quarterly average of 38.3 and 58% lower than its last 4 quarters average of 31.6
The price to sales (P/S) is 47% lower than the 5-year quarterly average of 11.9 and 8% lower than the last 4 quarters average of 6.8
The company's revenue rose by 21% YoY and by 8% QoQ
Efficiency
How efficient is Halozyme Therapeutics business performance
Halozyme Therapeutics's return on assets has increased by 46% YoY and by 13% QoQ
HALO's return on invested capital is up by 34% year-on-year and by 9% since the previous quarter
HALO's return on sales is up by 23% year-on-year and by 6% since the previous quarter
The ROE has contracted by 7% from the previous quarter and by 2.1% YoY
Dividends
What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HALO.
Financial health
How did Halozyme Therapeutics financials performed over time
The company's total assets is 27% higher than its total liabilities
Halozyme Therapeutics's quick ratio has soared by 57% from the previous quarter and by 44% YoY
The company's current ratio rose by 40% QoQ and by 36% YoY
The company's equity has surged by 82% YoY and by 56% QoQ
Halozyme Therapeutics's debt to equity has decreased by 45% YoY and by 36% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.